Stock listing
TPEx:6634 Sinew Pharma, Inc. (欣耀) 股價
Follow Sinew Pharma, Inc. into a list and get an email when it puts out news.
Share price · TPEX:6634
$52.90 TWD -7.10 (-11.8%)
Close on Nov 20, 2026
- Day range
- $50.90 – $57.00 TWDNov 20, 2026
- Volume
- 233,635 sharesNov 20, 2026
- Market cap
- $3.77B TWDAt the close on Nov 20, 2026 · price × 71.29M shares outstanding
- Traded on an average day
- $6.08M TWDMedian day 77,785 shares · 1 day with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · TPEX:6634 · TWD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $52.90 | -7.10 | -11.8% | $57.00 | $57.00 | $50.90 | 233,635 | |
| $60.00 | +2.30 | +4.0% | $58.00 | $61.80 | $58.00 | 204,625 | |
| $57.70 | -1.30 | -2.2% | $59.00 | $59.00 | $56.30 | 106,126 | |
| $59.00 | -0.90 | -1.5% | $59.90 | $59.90 | $56.30 | 144,375 | |
| $59.90 | -0.40 | -0.7% | $60.40 | $60.40 | $58.80 | 42,605 | |
| $60.30 | -2.90 | -4.6% | $63.30 | $65.20 | $58.30 | 199,549 | |
| $63.20 | +6.00 | +10.5% | $57.20 | $64.90 | $56.00 | 363,837 | |
| $57.20 | +0.50 | +0.9% | $56.70 | $58.00 | $55.10 | 44,422 | |
| $56.70 | +1.20 | +2.2% | $55.50 | $56.80 | $54.30 | 76,151 | |
| $55.50 | +2.00 | +3.7% | $52.50 | $55.50 | $47.65 | 115,662 | |
| $53.50 | -2.30 | -4.1% | $56.00 | $56.10 | $52.40 | 85,939 | |
| $55.80 | -0.40 | -0.7% | $56.40 | $57.80 | $53.50 | 97,995 | |
| $56.20 | -2.00 | -3.4% | $58.00 | $59.20 | $54.50 | 87,026 | |
| $58.20 | +4.20 | +7.8% | $54.00 | $58.50 | $53.80 | 79,419 | |
| $54.00 | -1.70 | -3.1% | $55.70 | $55.70 | $52.80 | 88,920 | |
| $55.70 | -0.10 | -0.2% | $55.70 | $55.80 | $54.10 | 15,172 | |
| $55.80 | -1.20 | -2.1% | $57.00 | $57.00 | $55.00 | 38,951 | |
| $57.00 | +1.50 | +2.7% | $55.60 | $57.20 | $54.80 | 69,529 | |
| $55.50 | +0.10 | +0.2% | $55.50 | $55.50 | $55.50 | 0 | |
| $55.40 | -2.30 | -4.0% | $57.80 | $58.20 | $53.90 | 95,505 | |
| $57.70 | -0.10 | -0.2% | $57.90 | $58.30 | $56.50 | 49,126 | |
| $57.80 | -0.40 | -0.7% | $58.20 | $58.20 | $56.30 | 16,226 | |
| $58.20 | -1.50 | -2.5% | $59.90 | $60.00 | $56.30 | 56,557 | |
| $59.70 | +2.90 | +5.1% | $58.00 | $61.10 | $58.00 | 56,150 | |
| $56.80 | -3.40 | -5.6% | $60.20 | $60.20 | $55.80 | 112,755 | |
| $60.20 | 0.00 | 0.0% | $60.00 | $60.20 | $58.00 | 73,053 | |
| $60.20 | -0.60 | -1.0% | $60.80 | $60.80 | $58.10 | 36,545 | |
| $60.80 | +0.80 | +1.3% | $60.20 | $60.80 | $58.50 | 40,788 | |
| $60.00 | -0.60 | -1.0% | $60.80 | $61.50 | $59.60 | 73,369 | |
| $60.60 | -1.20 | -1.9% | $61.40 | $64.20 | $59.90 | 108,944 | |
| $61.80 | -2.10 | -3.3% | $64.40 | $64.40 | $61.80 | 91,981 | |
| $63.90 | -2.30 | -3.5% | $65.30 | $66.20 | $62.00 | 146,612 | |
| $66.20 | +4.60 | +7.5% | $61.70 | $70.10 | $61.00 | 346,758 | |
| $61.60 | +0.50 | +0.8% | $61.50 | $61.90 | $60.00 | 109,806 | |
| $61.10 | +1.10 | +1.8% | $60.20 | $62.50 | $59.80 | 172,324 | |
| $60.00 | 0.00 | 0.0% | $60.00 | $60.40 | $58.80 | 54,486 | |
| $60.00 | 0.00 | 0.0% | $60.00 | $61.20 | $58.80 | 56,915 | |
| $60.00 | +1.80 | +3.1% | $60.00 | $61.00 | $58.80 | 26,546 | |
| $58.20 | -2.40 | -4.0% | $60.60 | $61.30 | $57.60 | 65,414 | |
| $60.60 | +3.60 | +6.3% | $57.00 | $61.20 | $57.00 | 141,473 | |
| $57.00 | -1.90 | -3.2% | $60.20 | $60.20 | $56.90 | 113,155 | |
| $58.90 | -0.30 | -0.5% | $59.00 | $60.00 | $57.80 | 151,723 | |
| $59.20 | +3.50 | +6.3% | $56.00 | $60.30 | $56.00 | 109,273 | |
| $55.70 | -4.50 | -7.5% | $58.30 | $59.00 | $54.60 | 164,231 | |
| $60.20 | +9.20 | +18.0% | $51.00 | $66.00 | $51.00 | 446,084 | |
| $51.00 | +1.05 | +2.1% | $50.00 | $51.00 | $47.55 | 59,433 | |
| $49.95 | -0.25 | -0.5% | $50.20 | $50.30 | $48.80 | 45,057 | |
| $50.20 | -3.30 | -6.2% | $53.50 | $53.50 | $48.30 | 419,790 | |
| $53.50 | +1.80 | +3.5% | $52.00 | $54.50 | $52.00 | 46,049 | |
| $51.70 | -0.10 | -0.2% | $51.10 | $51.70 | $50.50 | 49,185 | |
| $51.80 | -0.70 | -1.3% | $52.00 | $52.00 | $50.60 | 96,666 | |
| $52.50 | -3.20 | -5.7% | $55.80 | $55.80 | $51.80 | 216,087 | |
| $55.70 | -0.30 | -0.5% | $56.00 | $56.20 | $54.60 | 45,967 | |
| $56.00 | -2.40 | -4.1% | $57.00 | $57.90 | $55.10 | 130,294 | |
| $58.40 | -1.60 | -2.7% | $60.00 | $60.00 | $57.00 | 73,422 | |
| $60.00 | +0.10 | +0.2% | $58.80 | $60.20 | $58.60 | 18,240 | |
| $59.90 | +1.10 | +1.9% | $58.80 | $59.90 | $57.90 | 27,703 | |
| $58.80 | -0.90 | -1.5% | $60.00 | $60.20 | $57.80 | 55,955 | |
| $59.70 | -0.50 | -0.8% | $60.20 | $60.20 | $58.60 | 28,460 | |
| $60.20 | +0.10 | +0.2% | $60.90 | $63.20 | $58.80 | 115,553 | |
| $60.10 | +0.10 | +0.2% | $60.00 | $60.90 | $58.80 | 31,331 | |
| $60.00 | +0.10 | +0.2% | $60.00 | $60.00 | $57.00 | 14,595 |
- Ticker
- TPEx:6634
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- TPEx
- Currency
- TWD
Sinew Pharma, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
Valuation
EV/sales 59,064× against a median of 9.9×: the highest of 8 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $2.78B TWD
- P/E
- Loss
- EV/sales
- 59,064×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 3.6×
- Gross margin
- 78.7%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Sinew Pharma, Inc. · TPEX:6634 | US$114.4M | US$84.23M | n/a | 59,064× | n/a | 3.6× | n/a | 0.0× | n/a |
| STCube, Inc. · KRX:052020 | US$118.4M | US$72.43M | n/a | 13.6× | n/a | 2.6× | −338.7% | 0.0× | n/a |
| Atrium Therapeutics, Inc. · NASDAQ:RNA | US$118.4M | −US$113.0M | n/a | −2.9× | n/a | 0.6× | −229.7% | 0.0× | 0.76 |
| Adagene, Inc. · NASDAQ:ADAG | US$118.2M | −US$3.65M | n/a | −0.5× | n/a | 1.1× | −229.6% | 0.1× | 1.43 |
| Curacle Co., Ltd. · KRX:365270 | US$117.6M | US$100.4M | n/a | 16.3× | n/a | 3.4× | −92.1% | 0.0× | n/a |
| PegBio Co., Ltd. Class H · HKEX:2565 | US$117.2M | US$55.97M | n/a | n/a | n/a | 2.9× | n/a | 0.0× | n/a |
| enGene Therapeutics Inc. · NASDAQ:ENGN | US$116.6M | −US$149.7M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 1.82 |
| Armata Pharmaceuticals, Inc. · AMEX:ARMP | US$112.7M | US$346.0M | n/a | 45.8× | n/a | n/a | n/a | n/a | 0.97 |
| Medigen Biotechnology Corporation · TPEX:3176 | US$111.8M | US$61.95M | n/a | 1.6× | n/a | 2.5× | −19.9% | 0.8× | n/a |
| Fate Therapeutics, Inc. · NASDAQ:FATE | US$111.7M | US$47.08M | n/a | 9.9× | n/a | 0.8× | n/a | 0.6× | 2.25 |
| OnKure Therapeutics, Inc. · NASDAQ:OKUR | US$109.4M | −US$53.16M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 1.17 |
| Median of the others | US$116.9M | US$51.52M | 9.9× | 1.1× | −229.6% | 0.0× | 1.30 |
Team and board
Officers
| Officer | Role |
|---|---|
| Kai-Min Chu | Chairman & CEO |
| Tzu-Wen Chen | Chief Financial Officer |
| Cheng-Huei Hsiong | Chief Operating Officer |
| Chi-Chi Chou | Director of Quantitative Analysis Department |
| Hsin-Tien Ho | Chief Technology Officer |
Board
| Director | Role |
|---|---|
| Kai-Min Chu | Chairman & CEO |
Financials
Annual, in TWD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 47.0K | 0 | 0 | 328.0K | 6.23M | 462.0K | |
| Cost of revenue | 10.0K | 30.3M | 29.0M | 38.0K | 1.14M | 138.0K | |
| Gross profit | 37.0K | -30.3M | -29.0M | 290.0K | 5.09M | 324.0K | |
| Research and development | 97.5M | 113.6M | 133.5M | 114.6M | 72.7M | 66.7M | 60.3M |
| Selling, general and administrative | 42.7M | 37.0M | 34.7M | 34.1M | 26.8M | 17.7M | 16.6M |
| Operating income | -140.1M | -168.9M | -186.3M | -148.4M | -94.4M | -84.1M | -76.0M |
| Depreciation and amortization | 19.3M | 30.3M | 29.0M | 22.8M | 22.6M | 21.9M | 18.3M |
| EBITDA | -120.8M | -138.6M | -157.3M | -125.6M | -71.8M | -62.3M | -57.8M |
| Interest expense | 657.0K | 414.0K | 776.0K | 275.0K | 146.0K | 274.0K | 176.0K |
| Income before tax | -123.7M | -150.4M | -170.9M | -140.2M | -91.6M | -82.0M | -76.2M |
| Net income | -123.7M | -150.4M | -170.9M | -140.2M | -91.6M | -82.0M | -76.2M |
| Earnings per share, basic | -1.74 | -2.11 | -2.43 | -2.02 | -1.54 | -1.60 | -1.94 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 25.3M | 41.4M | 166.8M | 246.7M | 551.2M | 46.8M | 252.7M |
| Short-term investments | 1.03B | 1.12B | 1.11B | 1.14B | 931.5M | 291.5M | 40.0M |
| Receivables | 50.0K | 2.42M | 1.85M | 1.22M | 433.0K | 153.0K | |
| Current assets | 1.08B | 1.18B | 1.30B | 1.41B | 1.50B | 351.9M | 305.9M |
| Total assets | 1.13B | 1.23B | 1.36B | 1.49B | 1.58B | 453.2M | 420.8M |
| Current liabilities | 25.5M | 27.2M | 35.2M | 23.3M | 15.1M | 15.5M | 247.8M |
| Total debt | 2.82M | 9.28M | 7.54M | 1.05M | 3.34M | 5.18M | |
| Total liabilities | 36.4M | 28.9M | 39.7M | 28.7M | 16.0M | 17.4M | 252.0M |
| Shareholders' equity | 1.09B | 1.20B | 1.32B | 1.46B | 1.57B | 435.8M | 168.8M |
| Shares outstanding | 71.3M | 71.3M | 70.5M | 69.3M | 59.5M | 51.3M | 39.4M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -95.3M | -106.1M | -118.0M | -93.8M | -57.3M | -59.3M | -58.7M |
| Capital spending | -1.87M | -1.33M | -7.45M | -5.88M | -5.87M | -2.69M | -6.66M |
| Free cash flow | -97.2M | -107.4M | -125.5M | -99.6M | -63.2M | -62.0M | -65.4M |
| Cash from investing | -16.7M | 26.2M | -221.1M | -648.6M | -256.7M | 34.0M | |
| Cash from financing | -2.65M | 12.0M | 10.4M | 1.21B | 110.1M | 235.7M | |
| Change in cash | -16.1M | -125.4M | -79.9M | -304.5M | 504.3M | -205.9M | 210.9M |
Cap table
Built by 6ix from Sinew Pharma, Inc.’s releases
- Common shares
- 71,288,930
- Fully diluted
- 71,288,930
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 71,288,930 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 71,288,930 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Cheng-Huei Hsiong | Chief Operating Officer · Since at least Nov 5, 2026 |
| Chi-Chi Chou | Director of Quantitative Analysis Department · Since at least Nov 5, 2026 |
| Hsin-Tien Ho | Chief Technology Officer · Since at least Nov 5, 2026 |
| Kai-Min Chu | Chairman & CEO · Since at least Nov 5, 2026 |
| Tzu-Wen Chen | Chief Financial Officer · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Sinew Pharma, Inc.